QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS1-Region Domestic Shipping
What is SLU-PP-332?
SLU-PP-332 1mg is a higher-dose tablet formulation of the ERRα/ERRγ agonist SLU-PP-332 — doubling the per-tablet dose for research protocols requiring greater receptor occupancy or extended dose-response range. Same mechanism: PGC-1α coactivation, mitochondrial biogenesis, and β-oxidation gene upregulation. Research use only.
Research Applications
Dose-Response Studies
ERRα/γ activation across 500mcg–1mg–20mg–50mg–100mg concentration range
Mitochondrial Biogenesis
TFAM, NRF1/2, mtDNA copy number at higher receptor occupancy
Fatty Acid Oxidation
Higher-dose CPT1/ACADM/HADHA expression and β-oxidation flux
Exercise Mimetic Research
Dose-dependent endurance gene signature and metabolic adaptation
PGC-1α Pathway Activation
PGC-1α coactivation threshold, SIRT1 interaction, downstream effectors
Quick Specs
| Form | Tablet — 1mg per tablet, 100-tablet bottle |
| CAS Number | 2411025-13-3 |
| Molecular Formula | C₂₄H₂₃N₃O₃ |
| Molecular Weight | 405.5 g/mol |
| Compound Type | ERRα/ERRγ Nuclear Receptor Agonist |
| Purity | ≥99% by HPLC — every batch |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house synthesis — Qingdao, China |
| Storage | Room temperature sealed | cool, dry storage |
| Shelf Life | 24 months unopened |

